Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomised, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 16 weeks

Registry ID

EUCTR2009-011795-29

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Institut de Recherches Internationales Servier

Start date

2009-09-04

Completion date

2011-10-07

Last update

2026-08-16

Conditions

• Major Depression

Summary

Efficacy of agomelatine compared to placebo, in elderly out-patients suffering from Major Depressive Disorder.

Locations

• , , Finland
• , , Portugal

Related clinical trials

• Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
• NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
• RCT of At-Home tDCS for Depression in Pregnancy
• EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
• Effect of Psychobiotics With Standard Antiddepressants in Treatment of Major Depressive Disorder
• Inhaled DMT for Major Depressive Disorder

View on source registry